Clinical and Pharmacokinetic Trial of Intra-Abdominal Irinotecan

NCT00183859 | Completed Phase 1

• 1 other identifier: 0C-99-7
• Study Type: interventional
• Target: 42
• Locations: 1 country
• Sites: 1

Brief Summary

This is a research study for patients that have an advanced cancer that is confined mostly to the abdominal cavity and have failed treatment with conventional therapy, or for which no standard treatment exists. The purpose of this study is to determine the dose of a chemotherapy drug (called irinotecan) that can be administered safely into the abdominal cavity. We also wish to identify the side effects of irinotecan when it is administered directly into the abdomen. In this study, we will also determine the levels of irinotecan in the blood and in the abdominal cavity. Irinotecan is a chemotherapy drug that can decrease the size of several different tumors. It is approved by the FDA for the treatment of colon cancer. It appears that some other chemotherapy drugs are more effective and may have less side effects when they are administered directly into the abdomen.

Conditions

Adenocarcinoma; Gastric Cancer

Keywords

solid tumor; phase I; phase one

Outcome Measures

Primary Outcomes (1)

• To establish the maximum tolerated dose (MTD) of irinotecan when administered by an intra-peritoneal route every three weeks.

  6 weeks

Secondary Outcomes (2)

• To determine the pharmacokinetics of intra-peritoneal irinotecan.

  One day

• To determine the toxicity profile of intra-peritoneal irinotecan.

  30 days after patient receives last dose

Study Arms (1)

A

EXPERIMENTAL

Intraperitoneal Irinotecan

Drug: irinotecan

Interventions

irinotecan DRUG

Intraperitoneal Irinotecan given every three weeks

A

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Histologically confirmed recurrent, metastatic, or residual cancer with disease confined mostly to the peritoneal cavity. Patients with asymptomatic extra-peritoneal disease are eligible.
• Measurable or evaluable disease. Patients with malignant ascites or carcinomatosis only (documented by cytology or during surgery) are eligible. Patients with ovarian cancer and disease manifested only by an elevated CA-125 are also eligible.
• Adequate hepatic, renal, and bone marrow functions: bilirubin less than or equal to 2.0 mg/dl; creatinine less than or equal to 2.0 mg/dl, alkaline phosphatase less than or equal to 3 x upper limit of normal (uln), AST or ALT less than or equal to 3 x uln; AGC greater than or equal to 1500, platelets greater than or equal to 100,000.
• SWOG performance status 0-2
• Fully recovered from acute toxicities from prior surgery, chemotherapy, or radiation therapy.
• Patients must use an approved method of birth control.

You may not qualify if:

• Medical, social, or psychological factors which could prevent patient from receiving treatment.
• Prior therapy with intra-peritoneal irinotecan
• Significant intra-peritoneal adhesions detected clinically or by prior surgical exploration

Sponsors & Collaborators

• University of Southern California: lead

Study Sites (1)

U.S.C. / Norris Comprehensive Cancer Center

Los Angeles, California, 90033, United States

Location

MeSH Terms

Conditions

Adenocarcinoma; Stomach Neoplasms

Interventions

Irinotecan

Condition Hierarchy (Ancestors)

Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Gastrointestinal Diseases; Stomach Diseases

Intervention Hierarchy (Ancestors)

Camptothecin; Alkaloids; Heterocyclic Compounds

Study Officials

• Syma Iqbal, M.D.

  U.S.C. / Norris Comprehensive Cancer Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 9, 2005
• First Posted: September 16, 2005
• Study Start: September 1, 1999
• Primary Completion: April 1, 2009
• Study Completion: April 1, 2009
• Last Updated: May 22, 2014

Record last verified: 2014-05

Locations

US (1)